Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16389875 | 0.89 | HRH3 (0.47) | HRH3CYP1A2CYP2D6SMN1; SMN2NPC1 | |
| SCHEMBL2619347 | 0.88 | NFKB1 (0.54) | HRH3CYP1A2CYP2D6SMN1; SMN2NPC1 | |
| Ammonia Solution, Strong SCHEMBL7978427 | 0.86 | NFKB1 (0.53) | HRH3CYP1A2CYP2D6SMN1; SMN2NPC1 | |
| SCHEMBL31190152 | 0.86 | RAB9A (0.51) | HRH3CYP1A2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11575820 | 0.84 | RAB9A (0.54) | CYP1A2SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL10462081 | 0.84 | MCHR1 (0.44) | HRH3CYP1A2CYP2D6SMN1; SMN2NPC1 | |
| SCHEMBL30398570 | 0.84 | HRH3 (0.55) | HRH3CYP1A2CYP2D6SMN1; SMN2NPC1 | |
| SCHEMBL487617 | 0.84 | HRH3 (0.55) | HRH3CYP1A2CYP2D6SMN1; SMN2NPC1 | |
| SCHEMBL16935090 | 0.83 | TAAR1 (0.54) | HRH3CYP1A2CYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL18397243 | 0.83 | HRH3 (0.44) | HRH3CYP1A2CYP2D6SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503465-B2 | Process for preparing [3-chloro-2-[3-[2-[1-(2-chloroacetyl)-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]phenyl] methanesulfonate | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4077321-B1 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | BAYER AG (DE) | 2025-06-25 | — | — | EP | disclosed |
| CN-114829360-B | Process for preparing Fluoxapiprolin intermediates | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20230348462-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-11-02 | — | — | US | disclosed |
| US-11765968-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-19 | — | — | US | disclosed |
| US-11765968-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-19 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230031599-A1 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-02 | — | — | US | disclosed |
| EP-4077321-A1 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | Bayer Aktiengesellschaft (DE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114829360-A | Process for the preparation of [ 3-chloro-2- [3- [2- [1- (2-chloroacetyl) -4-piperidinyl ] thiazol-4-yl ] -4, 5-dihydroisoxazol-5-yl ] phenyl ] methanesulfonate | 拜耳公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20130274244-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2013-10-17 | — | — | US | disclosed |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2009023718-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-7164016-B2 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-16 | — | — | US | disclosed |
| US-7164016-B2 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | HRH3 38/4885CYP1A2 1353/4885CYP2D6 3069/4885 |
| US-20130274244-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | MUSK, FGFR1, FRK | HRH3 295/4885CYP1A2 2049/4885CYP2D6 2406/4885 |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | HRH3 170/4885CYP1A2 2003/4885CYP2D6 2509/4885 |
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | HRH3 3154/4885CYP1A2 1111/4885CYP2D6 1271/4885 |
| US-20230348462-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | HRH3 2354/4885CYP1A2 4119/4885CYP2D6 4472/4885 |
| US-12503465-B2 | Process for preparing [3-chloro-2-[3-[2-[1-(2-chloroacetyl)-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]phenyl] methanesulfonate | CTPS2, DCPS, DHPS | HRH3 3838/4885CYP1A2 451/4885CYP2D6 34/4885 |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | HRH3 28/4885CYP1A2 1215/4885CYP2D6 2312/4885 |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HRH3 36/4885CYP1A2 1772/4885CYP2D6 3113/4885 |
| US-20230031599-A1 | PROCESS FOR PREPARING [3-CHLORO-2-[3-[2-[1-(2-CHLOROACETYL)-4-PIPERIDYL]THIAZOL-4-YL]-4,5-DIHYDROISOXAZOL-5-YL]PHENYL] METHANESULFONATE | CTPS2, DCPS, DHPS | HRH3 3838/4885CYP1A2 451/4885CYP2D6 34/4885 |
| US-11765968-B2 | Organic electroluminescent materials and devices | TPR, TPO, DDT | HRH3 2490/4885CYP1A2 4306/4885CYP2D6 3468/4885 |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | HRH3 36/4885CYP1A2 1836/4885CYP2D6 2853/4885 |
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | PPARA, PPARG, PPARD | HRH3 819/4885CYP1A2 669/4885CYP2D6 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.